ArticleClinical case reports2025
Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor Necrosis Factor-alpha (TNF-α) inhibitors have been successfully used to treat rheumatoid arthritis (RA), psoriatic and ankylosing arthritis, and inflammatory bowel disease. While these inhibitors effectively decrease the inflammatory activity of immune-related disorders, they have been associated with central nervous system (CNS) and peripheral demyelination. In this study, we report a 44-year-old female patient with RA who developed neurological symptoms after a course of infliximab therapy due to tumefactive demyelinating lesions (TDLs). Imaging findings led to discontinuation of the drug and treatment with corticosteroids, resulting in clinical improvement. This case underscores the importance of monitoring neurological side effects during TNF-α therapy and early intervention when symptoms occur. Tumor necrosis factor-alpha inhibitors, such as infliximab, can unmask or induce demyelinating lesions, even in patients without prior multiple sclerosis. Prompt MRI evaluation and infliximab discontinuation, followed by corticosteroids, can lead to clinical improvement. Neurological assessment is recommended before initiating TNF-α inhibitors, especially in patients with risk factors for demyelination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.